Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126958490> ?p ?o ?g. }
- W3126958490 endingPage "234" @default.
- W3126958490 startingPage "223" @default.
- W3126958490 abstract "Combined-modality treatment consisting of chemotherapy and consolidation radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. However, the use of radiotherapy can have long-term sequelae, which is of particular concern, as Hodgkin lymphoma is frequently diagnosed in young adults with a median age of approximately 30 years. In the German Hodgkin Study Group HD17 trial, we investigated whether radiotherapy can be omitted without loss of efficacy in patients who have a complete metabolic response after receiving two cycles of escalated doses of etoposide, cyclophosphamide, and doxorubicin, and regular doses of bleomycin, vincristine, procarbazine, and prednisone (eBEACOPP) plus two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy (2 + 2).In this multicentre, open-label, randomised, phase 3 trial, patients (aged 18-60 years) with newly diagnosed early-stage unfavourable Hodgkin lymphoma (all histologies) and an Eastern Cooperative Oncology Group performance status of 2 or less were enrolled at 224 hospitals and private practices in Germany, Switzerland, Austria, and the Netherlands. Patients were randomly assigned (1:1) to receive either standard combined-modality treatment, consisting of the 2 + 2 regimen (eBEACOPP consisted of 1250 mg/m2 intravenous cyclophosphamide on day 1, 35 mg/m2 intravenous doxorubicin on day 1, 200 mg/m2 intravenous etoposide on days 1-3, 100 mg/m2 oral procarbazine on days 1-7, 40 mg/m2 oral prednisone on days 1-14, 1·4 mg/m2 intravenous vincristine on day 8 [maximum dose of 2 mg per cycle], and 10 mg/m2 intravenous bleomycin on day 8; ABVD consisted of 25 mg/m2 intravenous doxorubicin, 10 mg/m2 intravenous bleomycin, 6 mg/m2 intravenous vinblastine, and 375 mg/m2 intravenous dacarbazine, all given on days 1 and 15) followed by 30 Gy involved-field radiotherapy (standard combined-modality treatment group) or PET4-guided treatment, consisting of the 2 + 2 regimen followed by 30 Gy of involved-node radiotherapy only in patients with positive PET at the end of four cycles of chemotherapy (PET4; PET4-guided treatment group). Randomisation was done centrally and used the minimisation method and seven stratification factors (centre, age, sex, clinical symptoms, disease localisation, albumin concentration, and bulky disease), and patients and investigators were masked to treatment allocation until central review of the PET4 examination had been completed. With the final analysis presented here, the primary objective was to show non-inferiority of the PET4-guided strategy in a per-protocol analysis of the primary endpoint of progression-free survival. We defined non-inferiority as an absolute difference of 8% in the 5-year progression-free survival estimates between the two groups. Safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT01356680.Between Jan 13, 2012, and March 21, 2017, we enrolled and randomly assigned 1100 patients to the standard combined-modality treatment group (n=548) or to the PET4-guided treatment group (n=552); two patients in each group were found ineligible after randomisation. At a median follow-up of 46·2 months (IQR 32·7-61·2), 5-year progression-free survival was 97·3% (95% CI 94·5-98·7) in the standard combined-modality treatment group and 95·1% (92·0-97·0) in the PET4-guided treatment group (hazard ratio 0·523 [95% CI 0·226-1·211]). The between-group difference was 2·2% (95% CI -0·9 to 5·3) and excluded the non-inferiority margin of 8%. The most common grade 3 or 4 acute haematological adverse events were leucopenia (436 [83%] of 528 patients in the standard combined-modality treatment group vs 443 [84%] of 529 patients in the PET4-guided treatment group) and thrombocytopenia (139 [26%] vs 176 [33%]), and the most frequent acute non-haematological toxic effects were infection (32 [6%] vs 40 [8%]) and nausea or vomiting (38 [7%] vs 29 [6%]). The most common acute radiotherapy-associated adverse events were dysphagia (26 [6%] in the standard combined-modality treatment group vs three [2%] in the PET4-guided treatment group) and mucositis (nine [2%] vs none). 229 serious adverse events were reported by 161 (29%) of 546 patients in the combined-modality treatment group, and 235 serious adverse events were reported by 164 (30%) of 550 patients in the PET4-guided treatment group. One suspected unexpected serious adverse reaction (infection) leading to death was reported in the PET4-guided treatment group.PET4-negativity after treatment with 2 + 2 chemotherapy in patients with newly diagnosed early-stage unfavourable Hodgkin lymphoma allows omission of consolidation radiotherapy without a clinically relevant loss of efficacy. PET4-guided therapy could thereby reduce the proportion of patients at risk of the late effects of radiotherapy.Deutsche Krebshilfe." @default.
- W3126958490 created "2021-02-15" @default.
- W3126958490 creator A5003056562 @default.
- W3126958490 creator A5003363227 @default.
- W3126958490 creator A5013171926 @default.
- W3126958490 creator A5017330007 @default.
- W3126958490 creator A5020097248 @default.
- W3126958490 creator A5020907777 @default.
- W3126958490 creator A5028397596 @default.
- W3126958490 creator A5028510513 @default.
- W3126958490 creator A5036102646 @default.
- W3126958490 creator A5039994927 @default.
- W3126958490 creator A5040054777 @default.
- W3126958490 creator A5043426460 @default.
- W3126958490 creator A5044109674 @default.
- W3126958490 creator A5053252307 @default.
- W3126958490 creator A5055368093 @default.
- W3126958490 creator A5057387418 @default.
- W3126958490 creator A5059188766 @default.
- W3126958490 creator A5060345625 @default.
- W3126958490 creator A5061291419 @default.
- W3126958490 creator A5061498879 @default.
- W3126958490 creator A5062172926 @default.
- W3126958490 creator A5064132655 @default.
- W3126958490 creator A5065655150 @default.
- W3126958490 creator A5067856399 @default.
- W3126958490 creator A5068013617 @default.
- W3126958490 creator A5068698535 @default.
- W3126958490 creator A5071581236 @default.
- W3126958490 creator A5071753657 @default.
- W3126958490 creator A5075117420 @default.
- W3126958490 creator A5075974300 @default.
- W3126958490 creator A5076077834 @default.
- W3126958490 creator A5076460303 @default.
- W3126958490 creator A5082867129 @default.
- W3126958490 creator A5083085650 @default.
- W3126958490 creator A5083161940 @default.
- W3126958490 creator A5086766354 @default.
- W3126958490 date "2021-02-01" @default.
- W3126958490 modified "2023-10-18" @default.
- W3126958490 title "PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial" @default.
- W3126958490 cites W2010746974 @default.
- W3126958490 cites W2025318905 @default.
- W3126958490 cites W2039888190 @default.
- W3126958490 cites W2051650384 @default.
- W3126958490 cites W2101472190 @default.
- W3126958490 cites W2101873015 @default.
- W3126958490 cites W2109831529 @default.
- W3126958490 cites W2116610563 @default.
- W3126958490 cites W2121605135 @default.
- W3126958490 cites W2125616358 @default.
- W3126958490 cites W2125790189 @default.
- W3126958490 cites W2127055058 @default.
- W3126958490 cites W2131388913 @default.
- W3126958490 cites W2133218300 @default.
- W3126958490 cites W2133487516 @default.
- W3126958490 cites W2134592280 @default.
- W3126958490 cites W2140801657 @default.
- W3126958490 cites W2171187650 @default.
- W3126958490 cites W2173784372 @default.
- W3126958490 cites W2211631799 @default.
- W3126958490 cites W2243890309 @default.
- W3126958490 cites W2469052042 @default.
- W3126958490 cites W2473498748 @default.
- W3126958490 cites W2596050027 @default.
- W3126958490 cites W2765462510 @default.
- W3126958490 cites W2791789958 @default.
- W3126958490 cites W2909797130 @default.
- W3126958490 cites W2950084076 @default.
- W3126958490 cites W2972952899 @default.
- W3126958490 cites W2990683910 @default.
- W3126958490 cites W2991009694 @default.
- W3126958490 cites W4236235343 @default.
- W3126958490 doi "https://doi.org/10.1016/s1470-2045(20)30601-x" @default.
- W3126958490 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33539742" @default.
- W3126958490 hasPublicationYear "2021" @default.
- W3126958490 type Work @default.
- W3126958490 sameAs 3126958490 @default.
- W3126958490 citedByCount "77" @default.
- W3126958490 countsByYear W31269584902021 @default.
- W3126958490 countsByYear W31269584902022 @default.
- W3126958490 countsByYear W31269584902023 @default.
- W3126958490 crossrefType "journal-article" @default.
- W3126958490 hasAuthorship W3126958490A5003056562 @default.
- W3126958490 hasAuthorship W3126958490A5003363227 @default.
- W3126958490 hasAuthorship W3126958490A5013171926 @default.
- W3126958490 hasAuthorship W3126958490A5017330007 @default.
- W3126958490 hasAuthorship W3126958490A5020097248 @default.
- W3126958490 hasAuthorship W3126958490A5020907777 @default.
- W3126958490 hasAuthorship W3126958490A5028397596 @default.
- W3126958490 hasAuthorship W3126958490A5028510513 @default.
- W3126958490 hasAuthorship W3126958490A5036102646 @default.
- W3126958490 hasAuthorship W3126958490A5039994927 @default.
- W3126958490 hasAuthorship W3126958490A5040054777 @default.
- W3126958490 hasAuthorship W3126958490A5043426460 @default.
- W3126958490 hasAuthorship W3126958490A5044109674 @default.
- W3126958490 hasAuthorship W3126958490A5053252307 @default.
- W3126958490 hasAuthorship W3126958490A5055368093 @default.